CardioGenics Financial Statements From 2010 to 2025
| CGNH Stock | USD 0.0001 0.00 0.00% |
Check CardioGenics Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CardioGenics Holdings' main balance sheet or income statement drivers, such as , as well as many indicators such as . CardioGenics financial statements analysis is a perfect complement when working with CardioGenics Holdings Valuation or Volatility modules.
CardioGenics |
CardioGenics Holdings Company Shares Owned By Insiders Analysis
CardioGenics Holdings' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current CardioGenics Holdings Shares Owned By Insiders | 2.52 % |
Most of CardioGenics Holdings' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CardioGenics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 2.515% of CardioGenics Holdings are shares owned by insiders. This is 83.43% lower than that of the Biotechnology sector and 83.65% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 75.07% higher than that of the company.
CardioGenics Holdings Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CardioGenics Holdings's current stock value. Our valuation model uses many indicators to compare CardioGenics Holdings value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CardioGenics Holdings competition to find correlations between indicators driving CardioGenics Holdings's intrinsic value. More Info.CardioGenics Holdings is rated second in return on asset category among its peers. It is rated fourth in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value CardioGenics Holdings by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for CardioGenics Holdings' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About CardioGenics Holdings Financial Statements
Investors use fundamental indicators, such as CardioGenics Holdings' revenue or net income, to determine how well the company is positioned to perform in the future. Although CardioGenics Holdings' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. The company was founded in 1997 and is headquartered in Mississauga, Canada. Cardiogenics Holdings operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 4 people.
Currently Active Assets on Macroaxis
Other Information on Investing in CardioGenics Pink Sheet
CardioGenics Holdings financial ratios help investors to determine whether CardioGenics Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CardioGenics with respect to the benefits of owning CardioGenics Holdings security.